|

PLB1004 Clinical Trials

5 actively recruiting trials across 1 location

Also known as: Andamertinib

Pipeline

Phase 1: 1Phase 2: 3Phase 1/2: 1

Top Sponsors

  • Avistone Biotechnology Co., Ltd.5

Indications

  • Lung Cancer5
  • Non Small Cell Lung Cancer5
  • Cancer5

Other4 trials

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Phase 2
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Phase 2
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Phase 2
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Phase 1/2

Sacramento, California1 trial

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

University of California-Davis

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.